Johnson & Johnson Share Holder Equity 2010-2024 | JNJ

Johnson & Johnson share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Johnson & Johnson share holder equity for the quarter ending March 31, 2024 was $70.020B, a 1.2% decline year-over-year.
  • Johnson & Johnson share holder equity for 2023 was $68.774B, a 10.46% decline from 2022.
  • Johnson & Johnson share holder equity for 2022 was $76.804B, a 3.76% increase from 2021.
  • Johnson & Johnson share holder equity for 2021 was $74.023B, a 16.98% increase from 2020.
Johnson & Johnson Annual Share Holder Equity
(Millions of US $)
2023 $68,774
2022 $76,804
2021 $74,023
2020 $63,278
2019 $59,471
2018 $59,752
2017 $60,160
2016 $70,418
2015 $71,150
2014 $69,752
2013 $74,053
2012 $64,826
2011 $57,080
2010 $56,579
2009 $50,588
Johnson & Johnson Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $70,020
2023-12-31 $68,774
2023-09-30 $71,228
2023-06-30 $76,409
2023-03-31 $70,869
2022-12-31 $76,804
2022-09-30 $74,599
2022-06-30 $76,357
2022-03-31 $74,709
2021-12-31 $74,023
2021-09-30 $70,272
2021-06-30 $69,580
2021-03-31 $65,834
2020-12-31 $63,278
2020-09-30 $64,473
2020-06-30 $62,978
2020-03-31 $61,294
2019-12-31 $59,471
2019-09-30 $58,210
2019-06-30 $60,785
2019-03-31 $58,955
2018-12-31 $59,752
2018-09-30 $64,626
2018-06-30 $62,889
2018-03-31 $63,255
2017-12-31 $60,160
2017-09-30 $73,979
2017-06-30 $71,922
2017-03-31 $70,341
2016-12-31 $70,418
2016-09-30 $72,769
2016-06-30 $72,473
2016-03-31 $72,647
2015-12-31 $71,150
2015-09-30 $71,554
2015-06-30 $71,131
2015-03-31 $67,878
2014-12-31 $69,752
2014-09-30 $76,591
2014-06-30 $78,048
2014-03-31 $76,582
2013-12-31 $74,053
2013-09-30 $69,804
2013-06-30 $69,665
2013-03-31 $66,855
2012-12-31 $64,826
2012-09-30 $63,761
2012-06-30 $60,434
2012-03-31 $61,366
2011-12-31 $57,080
2011-09-30 $61,527
2011-06-30 $62,132
2011-03-31 $59,863
2010-12-31 $56,579
2010-09-30 $57,291
2010-06-30 $52,851
2010-03-31 $52,914
2009-12-31 $50,588
2009-09-30 $50,384
2009-06-30 $46,247
2009-03-31 $43,791
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $360.280B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $768.355B 111.05
Novo Nordisk (NVO) Denmark $608.375B 46.75
Merck (MRK) United States $332.026B 60.41
AbbVie (ABBV) United States $279.466B 14.44
AstraZeneca (AZN) United Kingdom $242.395B 21.07
Novartis AG (NVS) Switzerland $206.669B 14.65
Pfizer (PFE) United States $162.575B 20.20
Sanofi (SNY) $123.959B 11.69
Innoviva (INVA) United States $0.986B 6.93